TBG Diagnostics was established in 1999 and is a molecular diagnostics company which covers a full range of molecular diagnostic products that is able to detect diseases earlier than traditional methods.
TBG was acquired by Progen Pharmaceuticals Limited
(ASX:PGL) earlier this year.
Progen decided to restructure and then refocus the business and found that molecular diagnostics actually works for the market.
If you look at the global market of molecular diagnostics, the compound annual growth rate is up to 15 per cent annually and would be reaching something like US$25 billion in the year of 2024.
